Medium materiality6/10
Spyre Therapeutics price target lowered to $123 from $130 at Wedbush
Why it may matterVerify against the original reporting
Bearish signal with target cut and price decline.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wedbush lowers SYRE target to $123 from $130; current price $95.18; priceChangeSinceSignal -2.53.
- Wedbush lowers PT to $123; price $95.18; -2.53 since signal
Key facts
- 01
Target: $123
- 02
Posted price: $95.18
- 03
Analyst firm: Wedbush
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.